Jasper Therapeutics (JSPR) PT Lowered to $68 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Jasper Therapeutics (JSPR) Tops Q2 EPS by 12c
August 13, 2024 7:53 AM EDTJasper Therapeutics (NASDAQ: JSPR) reported Q2 EPS of ($0.97), $0.12 better than the analyst estimate of ($1.09).
For earnings history and earnings-related data on Jasper Therapeutics (JSPR) click here.
... More